{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&sponsor=Biogen",
    "query": {
      "sponsor": "Biogen",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 463,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=15&sponsor=Biogen&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&sponsor=Biogen&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T03:16:19.741Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01591551",
      "title": "NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Natalizumab (Tysabri)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Health Care, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2012-03",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 3,
      "location_summary": "Patchogue, New York • High Point, North Carolina • Portland, Oregon",
      "locations": [
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591551"
    },
    {
      "nct_id": "NCT01945359",
      "title": "Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rocky Mountain MS Research Group, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-09",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-10-16",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945359"
    },
    {
      "nct_id": "NCT05928585",
      "title": "A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune System Diseases",
        "Autoimmunity"
      ],
      "interventions": [
        {
          "name": "HIB210",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HI-Bio, A Biogen Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-06",
      "completion_date": "2024-06-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 1,
      "location_summary": "Hialeah, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05928585"
    },
    {
      "nct_id": "NCT06044337",
      "title": "A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subacute Cutaneous Lupus Erythematosus",
        "Chronic Cutaneous Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "BIIB059 (litifilimab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2023-10-03",
      "completion_date": "2029-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06044337"
    },
    {
      "nct_id": "NCT02776072",
      "title": "Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2978,
      "start_date": "2016-05",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 38,
      "location_summary": "Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Hanford",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02776072"
    },
    {
      "nct_id": "NCT02342704",
      "title": "Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        },
        {
          "name": "fingolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 111,
      "start_date": "2014-11-30",
      "completion_date": "2016-05-18",
      "has_results": true,
      "last_update_posted_date": "2017-06-09",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342704"
    },
    {
      "nct_id": "NCT03902002",
      "title": "A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone 50 mg capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2019-07-19",
      "completion_date": "2020-01-27",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 3,
      "location_summary": "Tustin, California • Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902002"
    },
    {
      "nct_id": "NCT04924153",
      "title": "A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "KCNT1-Related Epilepsy"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2021-08-17",
      "completion_date": "2023-08-29",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04924153"
    },
    {
      "nct_id": "NCT00223457",
      "title": "Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Factors that influence compliance",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1040,
      "start_date": "2004-04",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2007-01-25",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223457"
    },
    {
      "nct_id": "NCT03864614",
      "title": "A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "SAGE-217",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1515,
      "start_date": "2019-02-27",
      "completion_date": "2023-06-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-19T03:16:19.741Z",
      "location_count": 52,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03864614"
    }
  ]
}